Metastatic Cervical Cancer Withdrawn Phase 2 Trials for Sitravatinib (DB15036)

Also known as: Metastatic Cervical Cancers / Cervical Cancer Metastatic

IndicationStatusPhase
DBCOND0036674 (Metastatic Cervical Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05614453Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based ChemotherapyTreatment